These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33597857)

  • 21. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Liu Z; Yan A; Zhao J; Yang S; Song L; Liu Z
    Exp Neurol; 2021 Aug; 342():113740. PubMed ID: 33971218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
    Ba M; Kong M; Ma G
    Drug Des Devel Ther; 2015; 9():199-206. PubMed ID: 25565773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
    Nascimento GC; Bariotto-Dos-Santos K; Leite-Panissi CRA; Del-Bel EA; Bortolanza M
    Neurotox Res; 2018 Nov; 34(4):799-807. PubMed ID: 29611150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats.
    Huang Y; Shu H; Li L; Zhen T; Zhao J; Zhou X; Luo W
    ASN Neuro; 2018; 10():1759091418811021. PubMed ID: 30439288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
    Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B
    Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
    Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
    Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Aging on Levo-Dihydroxyphenylalanine- Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Nishijima H; Kimura T; Mori F; Wakabayashi K; Kinoshita I; Nakamura T; Kon T; Suzuki C; Tomiyama M
    Front Aging Neurosci; 2021; 13():650350. PubMed ID: 34054505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.
    Ba M; Kong M; Guan L; Yi M; Zhang H
    Oncotarget; 2016 Sep; 7(37):58802-58812. PubMed ID: 27613848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
    J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats.
    Chen G; Nie S; Han C; Ma K; Xu Y; Zhang Z; Papa SM; Cao X
    Front Neurosci; 2017; 11():112. PubMed ID: 28337120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats.
    Shi H; Yang X; Zhao H; Zhang S; Zu J; Zhang W; Shen X; Cui G; Hua F; Yan C
    Neuropsychiatr Dis Treat; 2015; 11():1331-7. PubMed ID: 26064051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
    Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carnosic Acid Alleviates Levodopa-Induced Dyskinesia and Cell Death in 6-Hydroxydopamine-lesioned Rats and in SH-SY5Y Cells.
    Lai CY; Lin CY; Wu CR; Tsai CH; Tsai CW
    Front Pharmacol; 2021; 12():703894. PubMed ID: 34434108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity.
    Lu DS; Chen C; Zheng YX; Li DD; Wang GQ; Liu J; Shi J; Zhang F
    Front Mol Neurosci; 2018; 11():155. PubMed ID: 29867347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.